Two cases of Bacillus Calmette-Guérin cystitis treated with hyperbaric oxygen.

Hyperbaric oxygen (HBO2) therapy is a UHMS-approved treatment for radiation cystitis and has been used for other causes of cystitis such as cyclophosphamide-induced hemorrhagic cystitis and interstitial cystitis, among others. Immunotherapy with Bacillus Calmette-Guérin (BCG) is the most effective treatment of non-muscle invasive bladder cancer. BCG acts as a non-specific stimulant of the reticuloendothelial system, causing a local inflammatory response. BCG attaches to bladder tumor cells as well as urothelial cells which then stimulates an immune response involving a multitude of cytokines and local migration of polymorphonuclear cells that leads to death of the cancer cells. The typical protocol of a single six-week course has been shown to provide long-term protection from tumor recurrence and to reduce disease progression. Irritative bladder side effects are common, but serious side effects are uncommon. Two cases of severe BCG-cystitis treated with HBO2 are presented. Two male patients with bladder cancer were treated with intravesicular BCG. Each developed complications of pain, spasms, urinary frequency and nocturia; one developed gross hematuria. Cystoscopy showed friable mucosa. They failed standard medical therapy and were referred for HBO2. They were treated in a multiplace chamber at 2.2-2.4 ATA. One patient received 60 and the other 40 treatments. Both experienced substantial reduction in their symptoms. BCG cystitis may be considered for HBO2 if other standard therapy has failed.

Hyperbaric programs in the United States: Locations and capabilities of treating decompression sickness, arterial gas embolisms, and acute carbon monoxide poisoning: survey results.

Hyperbaric oxygen therapy is the primary treatment for arterial gas embolism, decompression sickness and acute carbon monoxide poisoning. Though there has been a proliferation of hyperbaric centers throughout the United States, a scarcity of centers equipped to treat emergency indications makes transport of patients necessary. To locate and characterize hyperbaric chambers capable of treating emergency cases, a survey of centers throughout the entire United States was conducted. Using Google, Yahoo, HyperbaricLink and the UHMS directory, a database for United States chambers was created. Four researchers called clinicians from the database to administer the survey. All centers were contacted for response until four calls went unreturned or a center declined to be included. The survey assessed chamber readiness to respond to high-acuity patients, including staff availability, use of medical equipment such as ventilators and intravenous infusion devices, and responding yes to treating hyperbaric emergencies within a 12-month period. Only 43 (11.9%, N = 361) centers had equipment, intravenous infusion pumps and ventilators, and staff necessary to treat high-acuity patients. Considering that a primary purpose of hyperbaric oxygen therapy is the treatment of arterial gas embolism and decompression sickness, more hyperbaric centers nationwide should be able to accommodate these emergency cases quickly and safely.

CO and CO2 analysis in the diving gas of the fishermen of the Yucatan Peninsula.

It is reported that more than 75% of 400 artisanal fisherman divers working off the Yucatan Peninsula experience decompression sickness (DCS) each year, making DCS an epidemic in this region. These divers use primitive hookah diving support systems (HDSS). Breathing air is supplied from inadequately filtered and poorly maintained gasoline-powered air compressors. We hypothesized that air supplies could be contaminated. Air contamination could produce symptoms consistent with some presentations of DCS. This could confound and falsely elevate the true incidence of DCS. A cross-sectional study was undertaken in a fishing community. Ten fishermen from a single cohort participated. Fishermen were instructed not to drain volume tanks following their last dive of the day before their diving air was sampled. Dräger carbon monoxide (CO) 5/a-P and carbon dioxide (CO2) 100/a Short-term Tubes were used to measure 1.0 liters (L) of gas through a Visi-Float flow meter at 0.2 L/minute. Average CO value was 42 ppm (8-150 ppm). Average CO2 was 663 ppm (600-800). Measurements exceeded recommended diving norms for CO of 20 ppm. CO2 exceeded one diving organization recommendation of 500 ppm. Separation of engine exhaust from compressor intake could decrease CO values in HDSS to acceptable standards thus eliminating one possible confounder from this DCS epidemic.

Treatment of carbon monoxide poisoning with hyperbaric oxygen and therapeutic hypothermia.

We present a preliminary case report series of severe, acute carbon monoxide poisoning in which both hyperbaric oxygen (HBO2) and therapeutic hypothermia (TH) were used to ameliorate neurological sequelae. Carbon monoxide poisoning is a standard indication for HBO2. While typically used postcardiac arrest, TH has been used for other types of hypoxic-ischemic brain injury. Four patients were found comatose from carbon monoxide exposure. They were intubated and treated with high-flow oxygen before transfer to our hospital for HBO2. All received three HBO2 treatments and 24 hours of TH with a goal temperature of 33 degrees C utilizing the CoolGard 3000 Intravascular Temperature Management System. While in the HBO2 chamber, cooling was maintained with ice bags in the groin, axillae and under the head. Three of the four cases were discharged home with normal neurological exams. One patient sustained severe, diffuse brain injury yet made a dramatic neurological recovery with only minor limitations in higher order memory and attention. No patient left the hospital with other end organ damage including cardiac dysfunction. To our knowledge, these are the first reported cases of the use of both HBO2 and TH to treat severe, acute carbon monoxide poisoning.

Effective inspired oxygen concentration measured via transtracheal and oral gas analysis.

BACKGROUND: The fraction of inspired oxygen (F(IO(2))) is quoted for different oxygen delivery systems, but variations in inspiratory flow and tidal volume make precise measurement difficult. We developed a reliable method of measuring the effective F(IO(2)) in patients receiving supplemental oxygen. METHODS: Ten subjects with chronic hypoxemia breathed through a mouthpiece with a sampling probe connected to a mass spectrometer. Four of the 10 subjects had transtracheal catheters that allowed direct sampling of tracheal gas. We used oxygen concentrations of 47% and 97%, and flow rates between 1 L/min and 8 L/min. We also compared oxygen delivery via nasal cannula and transtracheal catheter. Effective F(IO(2)) was derived from plots of the fractional concentrations of carbon dioxide versus oxygen. RESULTS: We found excellent correlation between the effective F(IO(2)) values from tracheal and oral sampling (r = 0.960, P < .001). With 97% oxygen via nasal cannula, effective F(IO(2)) increased by 2.5% per liter of increased flow (P < .001); effective F(IO(2)) reached 32.7% at 5 L/min while P(aO(2)) increased by 12 mm Hg per liter of increased flow. In 4 subjects with a transtracheal catheter, effective F(IO(2)) increased 5.0% (P < .001) per liter of increased flow, and P(aO(2)) increased by 13 mm Hg per liter of increased flow, whereas in the same 4 subjects using nasal cannula for oxygen delivery, P(aO(2)) increased by only 6 mm Hg per liter of increased flow. CONCLUSIONS: Exhaled gas sampled at the mouth accurately reflected the effective F(IO(2)) in the trachea. In relation to inspired oxygen flow, the effective F(IO(2)) was lower than is conventionally thought. Compared to nasal cannula, transtracheal catheter approximately doubled the effective F(IO(2)) at a given flow rate. Accurate knowledge of F(IO(2)) should aid clinicians in managing patients with acute and chronic lung diseases.

Rehabilitation in non-COPD: mechanisms of exercise limitation and pulmonary rehabilitation for patients with pulmonary fibrosis/restrictive lung disease.

The standard of care in the treatment of chronic lung disease includes pulmonary rehabilitation (PR). While evidence of the effectiveness of PR in chronic obstructive lung disease (COPD) is robust, that for pulmonary fibrosis and other non-fibrotic restrictive lung diseases is less extensive. However, PR has been shown to improve functional exercise capacity and health-related quality of life in non-COPD patients, primarily those with interstitial lung diseases. This review examines mechanisms of exercise limitation in non-COPD patients and discusses how they might affect both the application of and outcome measures of PR. We also review the assessment of exercise performance, dyspnea, and quality of life as well as special protocols, safety considerations, and special techniques in PR as applied to patients with pulmonary fibrosis or restrictive lung disease. At present, there are no evidence-based guidelines for PR in non-COPD patients whereas PR is firmly recommended in COPD management. More research is needed to strengthen the evidence for the use of PR in non-COPD patients. Meanwhile, the available data, summarized in this review, support the inclusion of PR in the management of all patients with chronic lung disease including pulmonary fibrosis and restrictive lung disease.